DK1631312T3 - Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom - Google Patents
Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdomInfo
- Publication number
- DK1631312T3 DK1631312T3 DK04750581T DK04750581T DK1631312T3 DK 1631312 T3 DK1631312 T3 DK 1631312T3 DK 04750581 T DK04750581 T DK 04750581T DK 04750581 T DK04750581 T DK 04750581T DK 1631312 T3 DK1631312 T3 DK 1631312T3
- Authority
- DK
- Denmark
- Prior art keywords
- inflammatory bowel
- bowel disease
- treatment
- composition
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46515503P | 2003-04-23 | 2003-04-23 | |
PCT/US2004/012651 WO2004093908A2 (en) | 2003-04-23 | 2004-04-23 | Compositions and methods for the therapy of inflammatory bowel disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1631312T3 true DK1631312T3 (da) | 2009-01-19 |
Family
ID=33311000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04750581T DK1631312T3 (da) | 2003-04-23 | 2004-04-23 | Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom |
Country Status (22)
Country | Link |
---|---|
US (2) | US7939076B2 (da) |
EP (1) | EP1631312B1 (da) |
JP (1) | JP4628357B2 (da) |
KR (1) | KR100817351B1 (da) |
CN (2) | CN101318019B (da) |
AT (1) | ATE407698T1 (da) |
AU (1) | AU2004232362C1 (da) |
BR (1) | BRPI0410495A (da) |
CA (2) | CA2522957C (da) |
DE (1) | DE602004016499D1 (da) |
DK (1) | DK1631312T3 (da) |
ES (1) | ES2313039T3 (da) |
HK (1) | HK1082200A1 (da) |
IL (1) | IL171356A (da) |
MX (1) | MXPA05011409A (da) |
NZ (1) | NZ542866A (da) |
PL (1) | PL1631312T3 (da) |
PT (1) | PT1631312E (da) |
SG (1) | SG173919A1 (da) |
SI (1) | SI1631312T1 (da) |
WO (1) | WO2004093908A2 (da) |
ZA (1) | ZA200508390B (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ542866A (en) | 2003-04-23 | 2009-07-31 | Medarex Inc | Compositions and methods for the therapy of inflammatory bowel disease |
ES2368737T3 (es) * | 2003-04-23 | 2011-11-21 | Medarex, Inc. | Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1). |
US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
AU2005258077C1 (en) | 2004-06-21 | 2012-10-25 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
KR101166901B1 (ko) | 2010-04-16 | 2012-07-19 | 송영완 | 임플란트용 주입기 |
JP2013528622A (ja) * | 2010-06-04 | 2013-07-11 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 炎症性障害の処置 |
KR102157718B1 (ko) * | 2010-07-26 | 2020-09-18 | 큐 바이올로직스 인코포레이티드 | 면역원성 소염 조성물 |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
EP2951283A4 (en) | 2013-02-04 | 2017-01-25 | Seres Therapeutics, Inc. | Compositions and methods |
AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
KR102379658B1 (ko) | 2013-11-25 | 2022-03-28 | 세레스 테라퓨틱스, 인코포레이티드 | 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도 |
US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
AU2015252726B2 (en) | 2014-05-02 | 2020-12-24 | Qu Biologics Inc. | Anti-microbial immunomodulation |
EP3179985A1 (en) * | 2014-08-14 | 2017-06-21 | Brown University | Compositions for stabilizing and delivering proteins |
WO2016100301A1 (en) | 2014-12-15 | 2016-06-23 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders |
WO2018010140A1 (zh) | 2016-07-14 | 2018-01-18 | 中国科学院生物物理研究所 | I型干扰素受体抗体及其用途 |
EP3630146A1 (en) * | 2017-06-02 | 2020-04-08 | Goodgut S.L. | Grape skin for use in the treatment of dysbiosis |
EP3668527A1 (en) | 2017-08-14 | 2020-06-24 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
EP3672986A1 (en) | 2017-08-22 | 2020-07-01 | Sanabio, LLC | Soluble interferon receptors and uses thereof |
CN112056275B (zh) * | 2020-09-27 | 2022-05-10 | 澎立生物医药技术(上海)有限公司 | 一种肠粘膜炎动物模型及其构建方法和应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5516515A (en) * | 1986-02-05 | 1996-05-14 | Interferon Sciences, Inc. | Separation of alpha interferon receptor proteins and antibodies therefor |
IL78444A (en) * | 1986-04-08 | 1992-05-25 | Yeda Res & Dev | Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody |
IL88377A (en) | 1988-11-14 | 1996-09-12 | Yeda Res & Dev | Cloning and expression of a protein which modulates cellular response to type I interferon |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5889151A (en) * | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
FR2653445B1 (fr) | 1989-10-20 | 1994-07-29 | Centre Nat Rech Scient | Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante. |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
EP0601052B1 (en) | 1991-08-30 | 1996-10-16 | Genentech, Inc. | Therapeutic method for the treatment of iddm |
EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
WO1994014467A1 (en) * | 1992-12-29 | 1994-07-07 | Genentech, Inc. | Treatment of inflammatory bowel disease with ifn-gamma inhibitors |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
AU7782894A (en) * | 1993-09-17 | 1995-04-03 | Laboratoire Europeen De Biotechnologie S.A. | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
AU1289595A (en) | 1993-11-15 | 1995-06-06 | Cell Therapeutics, Inc. | Method for selectively inhibiting il-2 signal transduction |
US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
ES2229673T3 (es) * | 1998-01-30 | 2009-08-04 | Allertein Therapeutics, Llc | Ensayo para pronosticar alergia o inflamacion. |
AUPP670698A0 (en) | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
US6329159B1 (en) * | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
DE60037896D1 (de) | 1999-07-29 | 2008-03-13 | Medarex Inc | Menschliche antikörper gegen her2/neu |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
GB0001712D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
JP4156324B2 (ja) | 2002-09-30 | 2008-09-24 | ローム株式会社 | 直流−交流変換装置、及び交流電力供給方法 |
ES2368737T3 (es) * | 2003-04-23 | 2011-11-21 | Medarex, Inc. | Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1). |
NZ542866A (en) | 2003-04-23 | 2009-07-31 | Medarex Inc | Compositions and methods for the therapy of inflammatory bowel disease |
PT1711207E (pt) * | 2003-12-10 | 2013-02-13 | Medarex Inc | Anticorpos alfa interferão e seus usos |
AU2005258077C1 (en) * | 2004-06-21 | 2012-10-25 | E. R. Squibb & Sons, L.L.C. | Interferon alpha receptor 1 antibodies and their uses |
-
2004
- 2004-04-23 NZ NZ542866A patent/NZ542866A/xx not_active IP Right Cessation
- 2004-04-23 WO PCT/US2004/012651 patent/WO2004093908A2/en active Application Filing
- 2004-04-23 DE DE602004016499T patent/DE602004016499D1/de not_active Expired - Lifetime
- 2004-04-23 CN CN2008101102238A patent/CN101318019B/zh not_active Expired - Fee Related
- 2004-04-23 MX MXPA05011409A patent/MXPA05011409A/es active IP Right Grant
- 2004-04-23 SI SI200430937T patent/SI1631312T1/sl unknown
- 2004-04-23 CA CA2522957A patent/CA2522957C/en not_active Expired - Fee Related
- 2004-04-23 SG SG2007007115A patent/SG173919A1/en unknown
- 2004-04-23 BR BRPI0410495-1A patent/BRPI0410495A/pt not_active Application Discontinuation
- 2004-04-23 PT PT04750581T patent/PT1631312E/pt unknown
- 2004-04-23 US US10/831,432 patent/US7939076B2/en not_active Expired - Fee Related
- 2004-04-23 EP EP04750581A patent/EP1631312B1/en not_active Expired - Lifetime
- 2004-04-23 AT AT04750581T patent/ATE407698T1/de active
- 2004-04-23 DK DK04750581T patent/DK1631312T3/da active
- 2004-04-23 ES ES04750581T patent/ES2313039T3/es not_active Expired - Lifetime
- 2004-04-23 KR KR1020057020211A patent/KR100817351B1/ko not_active IP Right Cessation
- 2004-04-23 CN CNB2004800105953A patent/CN100409897C/zh not_active Expired - Fee Related
- 2004-04-23 CA CA2823468A patent/CA2823468A1/en not_active Abandoned
- 2004-04-23 AU AU2004232362A patent/AU2004232362C1/en not_active Ceased
- 2004-04-23 JP JP2006513278A patent/JP4628357B2/ja not_active Expired - Fee Related
- 2004-04-23 PL PL04750581T patent/PL1631312T3/pl unknown
-
2005
- 2005-10-10 IL IL171356A patent/IL171356A/en not_active IP Right Cessation
- 2005-10-17 ZA ZA200508390A patent/ZA200508390B/xx unknown
-
2006
- 2006-03-20 HK HK06103497.6A patent/HK1082200A1/xx not_active IP Right Cessation
-
2011
- 2011-03-17 US US13/050,601 patent/US8828393B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease | |
HRP20181459T1 (hr) | Humanizirani antagonisti anti-beta7 i njihove uporabe | |
NO20091734L (no) | Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse | |
DK1874818T3 (da) | TGF-Beta 1-specifikke antistoffer | |
DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
DE60142614D1 (de) | Inität | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
PE20061115A1 (es) | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos | |
ATE387435T1 (de) | Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren | |
ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
DK1383919T3 (da) | Fremgangsmåder og sammensætninger til anvendelse af MHC klasse II-invariant kædepolypeptid som en receptor for makrofag migrationsinhiberede faktor | |
ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
NO20054238D0 (no) | Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse | |
EA200601220A1 (ru) | Анти-trkc антитела-агонисты и способы их применения |